CELLINK publishes prospectus and new financial information due to admission to trading of shares of series B on Nasdaq Stockholm
At the extraordinary general meeting of CELLINK AB (publ) (“CELLINK” or the “Company”) on September 11, 2020, a directed share issue resolved by the board of directors of 1,625,000 shares of series B to a Swedish institutional investor approached in advance was approved. Due to this, the board of directors of CELLINK has prepared a prospectus for admission to trading of the shares, which has today been approved and registered by the Swedish Financial Supervisory Authority (“SFSA”). The prospectus contains, due to regulatory requirements, updated financial information as of July 31, 2020, attributable to the Company’s equity and liabilities and net indebtedness as well as consolidated pro forma accounts in regard to the acquisition of Scienion AG.
The prospectus
The prospectus has today, on September 18, 2020, been approved and registered by the SFSA, and is available on CELLINK’s website, www.cellink.com, and will be available on SFSA’s website, https://fi.se/sv/vara-register/prospektregistret/), within a few days.
The prospectus contains previously unpublished financial information attributable to CELLINK’s equity and liabilities and net indebtedness and assets as of July 31, 2020. The financial information is presented in the light of regulatory requirements, entailing that financial information regarding the capital structure must not be older than 90 days when the prospectus is published. Note that only interest-bearing liabilities are reported in the tables below. The information has not been reviewed by the Company’s auditor.
The prospectus also contains consolidated pro forma accounts for CELLINK, including Scienion AG, with a consolidated income statement regarding the period September 1, 2019 to May 31, 2020 and a consolidated balance sheet as of May 31, 2020.
The newly issued shares of series B are expected to be admitted to trading no later than on September 24, 2020.
The prospectus has been prepared in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The prospectus has been approved by the SFSA in accordance with the Prospectus Regulation. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of CELLINK or as an endorsement of the quality of the securities that are the subject of the prospectus and does not indicate that the Swedish Financial Supervisory Authority guarantees that the facts in the prospectus are correct or complete.
Updated financial information regarding equity and liabilities and net indebtedness
Equity and liabilities
| TSEK | |
| 2020-07-31 | |
| Total Current debt | |
| Guaranteed | 0 |
| Secured3 | 2 000 |
| Unguaranteed/Unsecured1 | 36 273 |
| Sum total current debt | 38 273 |
| Total Non-Current debt | |
| Guaranteed | 0 |
| Secured3 | 7 000 |
| Unguaranteed/Unsecured2 | 41 346 |
| Sum total non-current debt | 48 346 |
| Shareholder’s equity | |
| Share capital | 1 072 |
| Other contributed capital | 921 009 |
| Reserves | -13 081 |
| Retained earning4 | -45 931 |
| None-controlling influence | 3 202 |
| Sum shareholder’s equity | 866 271 |
| 1 Trade payables and other short-term non-interest bearing liabilities, as well as short-term interest bearing lease liability.2 Loan from Västra Götalandsregionen 600 TSEK, warranty reserve, deferred tax liabilities and long-term interest bearing lease liability.3 Loan from SEB totalling 9 000 KSEK, with quarterly installments of 500 KSEK. 4 Retained earnings is stated as per 2020-05-31. | |
Net indebtedness
| TSEK | 2020-07-31 |
| (A) Cash | - |
| (B) Cash equivalent | 97 473 |
| (C) Trading securities | 239 897 |
| (D) Liquidity (A)+(B)+(C) | 337 370 |
| (E) Current Financial Receivable | 58 634 |
| (F) Current Bank debt | 2 000 |
| (G) Current portion of non current debt | - |
| (H) Other current cinancial debt | 8 659 |
| (I) Current Financial Debt (F)+(G)+(H) | 10 659 |
| (J) Net Current Financial Indebtedness (I)-(E)-(D) | -385 345 |
| (K) Non current Bank loans | 7 000 |
| (L) Bonds Issued | - |
| (M) Other non current loans | 25 380 |
| (N) Non current Financial Indebtedness (K)+(L)+(M) | 32 380 |
| (O) Net Financial Indebtedness (J)+(N) | -352 965 |
Legal adviser
Advokatfirman Vinge has acted as legal adviser to CELLINK in connection to the preparation of the prospectus.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
E-mail: eg@cellink.com E-mail: gd@cellink.com
This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on September 18, 2020 at 10.30 CEST.
About CELLINK
CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.
Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.